Hemostemix Inchttps://investorshangout.com/Hemostemix-Inc-HMTXF-94216/en-usWed, 23 Sep 2026 01:38:42 GMTCopyright InvestorsHangout.comrodman: Buying opportunity so monitor big volume soon to arrive IMO! $.50+https://investorshangout.com/post/view?id=6752514https://investorshangout.com/post/view?id=6752514Thu, 27 Mar 2025 18:34:18 GMTrodman: You gotta believe in the efficacy of stem cell treatments? No doubt after a half cc injection to myhttps://investorshangout.com/post/view?id=6752224https://investorshangout.com/post/view?id=6752224Wed, 26 Mar 2025 12:54:34 GMTrodman: This is a head scratcher! That is in regard to revenue projections that can be verified. So much conhttps://investorshangout.com/post/view?id=6750095https://investorshangout.com/post/view?id=6750095Thu, 13 Mar 2025 16:28:16 GMTrodman: HMTXF headed up after the new cost cutting agreement! Hemostemix Licenses CytoImmunes BioReactohttps://investorshangout.com/post/view?id=6746162https://investorshangout.com/post/view?id=6746162Fri, 21 Feb 2025 12:49:05 GMTWilliammax: $HEM's stock performance throughout the year has been nothing short of disappointing, leaving investhttps://investorshangout.com/post/view?id=6639116https://investorshangout.com/post/view?id=6639116Tue, 31 Oct 2023 12:54:03 GMTJames Macho: $HEM's disappointing stock performance raises concerns about its long-term viability as an investmenhttps://investorshangout.com/post/view?id=6638650https://investorshangout.com/post/view?id=6638650Mon, 30 Oct 2023 13:49:44 GMTMatthewDavies: Hemostemix Inc. (TSXV: $HEM) (OTCQB: https://investorshangout.com/post/view?id=6489326https://investorshangout.com/post/view?id=6489326Tue, 25 Oct 2022 17:29:19 GMTJack Mallick: Hemostemix employed MR. Thomas Abraham as President of PreCerv Inc. which is an entirely owned entithttps://investorshangout.com/post/view?id=6488236https://investorshangout.com/post/view?id=6488236Fri, 21 Oct 2022 16:34:38 GMTrobert_brat: Hemostemix market cap broadens. Hemostemix's Insert-tag-here$HMTXhttps://investorshangout.com/post/view?id=6418317https://investorshangout.com/post/view?id=6418317Thu, 09 Jun 2022 15:56:00 GMTMatthewDavies: $HMTXF a publicly traded stock on https://investorshangout.com/post/view?id=6410015https://investorshangout.com/post/view?id=6410015Wed, 25 May 2022 16:58:56 GMTMatthewDavies: Hemostemix Inc. (OTCQB: HMTXF) won the Wohttps://investorshangout.com/post/view?id=6409966https://investorshangout.com/post/view?id=6409966Wed, 25 May 2022 16:05:24 GMTMatthewDavies: $HMTXF an volatile stohttps://investorshangout.com/post/view?id=6409156https://investorshangout.com/post/view?id=6409156Tue, 24 May 2022 14:51:57 GMTMatthewDavies: Rick Groome would be a valuable addition to https://investorshangout.com/post/view?id=6408405https://investorshangout.com/post/view?id=6408405Mon, 23 May 2022 15:18:22 GMTMatthewDavies: ACP-01 leaves its imprint. Hemostemixhttps://investorshangout.com/post/view?id=6406503https://investorshangout.com/post/view?id=6406503Thu, 19 May 2022 15:56:19 GMTMatthewDavies: Thomas Smeenk of Hemostemix HMTXF talks ahttps://investorshangout.com/post/view?id=6405753https://investorshangout.com/post/view?id=6405753Wed, 18 May 2022 16:33:38 GMTIR_CONSULTING_HEAD: The company’s lead candidate for phase 2 clinical-stage trial is doing wonders in medicine, aiding shttps://investorshangout.com/post/view?id=6382737https://investorshangout.com/post/view?id=6382737Wed, 13 Apr 2022 14:20:21 GMTIR_CONSULTING_HEAD: The company's market capitalization is at $10.2M, holding the water from flooding in like a sturdy hhttps://investorshangout.com/post/view?id=6382735https://investorshangout.com/post/view?id=6382735Wed, 13 Apr 2022 14:18:58 GMTIR_CONSULTING_HEAD: Hemostemix has completed a detailed audit of the data received to ensure the authenticity is intact.https://investorshangout.com/post/view?id=6382733https://investorshangout.com/post/view?id=6382733Wed, 13 Apr 2022 14:17:38 GMTIR_CONSULTING_HEAD: The ongoing dispute between aspiring health science has finally met its end as all the classified dahttps://investorshangout.com/post/view?id=6382731https://investorshangout.com/post/view?id=6382731Wed, 13 Apr 2022 14:15:57 GMTIR_CONSULTING_HEAD: Hemostemix is a biotechnology-based clinical-stage company listed on the OTC market with the ticker https://investorshangout.com/post/view?id=6382715https://investorshangout.com/post/view?id=6382715Wed, 13 Apr 2022 14:06:28 GMT